JG
DNLI icon

Joel Greenblatt’s Denali Therapeutics DNLI Stock Holding History

Joel Greenblatt’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,391
Closed -$400K – 1354
2023
Q3 		$400K Buy
+19,391
New +$492K 0.01% 1031
2023
Q1 		– Sell
-13,029
Closed -$362K – 1340
2022
Q4 		$362K Sell
13,029
-1,578
-11% -$47K 0.01% 993
2022
Q3 		$448K Sell
14,607
-678
-4% -$22K 0.01% 874
2022
Q2 		$450K Buy
+15,285
New +$400K 0.01% 816
2021
Q4 		– Sell
-5,317
Closed -$268K – 1157
2021
Q3 		$268K Sell
5,317
-4,222
-44% -$238K 0.01% 878
2021
Q2 		$748K Sell
9,539
-15,702
-62% -$971K 0.03% 572
2021
Q1 		$1.44M Buy
25,241
+17,646
+232% +$1.18M 0.06% 367
2020
Q4 		$636K Buy
+7,595
New +$459K 0.02% 659

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's DNLI Position: Q4 2023 in Review

Joel Greenblatt sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 19,391 shares — an estimated $400K sold.

Joel Greenblatt first reported a position in DNLI in Q4 2020 and held it in 8 quarters. The position peaked at $1.44M in Q1 2021. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

  • Joel Greenblatt reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Joel Greenblatt sold 19,391 Denali Therapeutics shares in Q4 2023, an estimated $400K.
  • Joel Greenblatt first reported a position in Denali Therapeutics in Q4 2020 and held it in 8 quarters.
  • Joel Greenblatt's Denali Therapeutics position peaked at $1.44M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on Gotham Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.